Industry: Pharmaceuticals, Biotechnology
Corautus Genetics is a clinical-stage biopharmaceutical company dedicated to the development of gene transfer therapy products for the treatment of cardiovascular (severe angina) and peripheral vascular disease. Corautus has been developing a gene therapy product candidate using the VEGF-2 gene to promote therapeutic angiogenesis in ischemic muscle. Corautus has a strategic alliance with Boston Scientific Corporation to develop, commercialize and distribute the VEGF-2 gene therapy products. ( www.corautus.com )
Corautus Genetics Inc.
75 Fifth Street, NW Suite 700
Atlanta, Georgia 30308
USA
Tel: (404) 526-6212
Fax: (404) 526-6218